Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis

Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis

Prostate cancer (PCa) is the most common malignancy in men. Despite aggressive therapy involving surgery and hormonal treatments, the recurrence and emergence of metastatic castration-resistant prostate cancer (CRPCa) remain a major challenge. Dysregulation of the transforming growth factor-β (TGF-β...

Full description

Bibliographic Details
Main Authors:	Bakhya Shree, Koyel Das, Vivek Sharma
Format:	Article
Language:	English
Published:	Elsevier 2023-07-01
Series:	Cancer Pathogenesis and Therapy
Subjects:	Prostate cancer TGF-β LncRNA Castration-resistant prostate cancer Androgen deprivation therapy Androgen-independent prostate cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S294971322200026X

Similar Items

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

Cell‐by‐cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression
by: Seta Derderian, et al.
Published: (2023-07-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

How to Optimally Sequence Available Therapy Lines in Advanced Prostate Cancer
by: Katarina Antunac
Published: (2022-01-01)

Clamp ablation of the testes compared to bilateral orchiectomy as androgen deprivation therapy for advanced prostate cancer
by: AD Zarrabi, et al.
Published: (2011-06-01)

Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants
by: Demitria M. Vasilatis, et al.
Published: (2023-04-01)

Distribution and Effects of Estrogen Receptors in Prostate Cancer: Associated Molecular Mechanisms
by: Adrián Ramírez-de-Arellano, et al.
Published: (2022-01-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004
by: R Miralbell, et al.
Published: (2009-09-01)

Interaction between Non-Coding RNAs and Androgen Receptor with an Especial Focus on Prostate Cancer
by: Mohammad Taheri, et al.
Published: (2021-11-01)

Expansion of mouse castration-resistant intermediate prostate stem cells in vitro
by: Yalan Xu, et al.
Published: (2022-07-01)

Clinical relevance of androgen receptor alterations in prostate cancer
by: Emma Jernberg, et al.
Published: (2017-10-01)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
by: Alexander Yaney, et al.
Published: (2022-06-01)

Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
by: Marzieh Ehsani, et al.
Published: (2021-03-01)

Androgen-Independent Prostate Cancer Is Sensitive to CDC42-PAK7 Kinase Inhibition
by: Hyunho Han, et al.
Published: (2022-12-01)

Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer
by: Crawford ED, et al.
Published: (2020-07-01)

Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy
by: Masaki eShiota, et al.
Published: (2016-01-01)

Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
by: Mauro Scaravilli, et al.
Published: (2021-02-01)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
by: Qin Feng, et al.
Published: (2019-09-01)

Long non-coding RNAs in castration-resistant and neuroendocrine prostate cancer: Potential role and therapeutic impact
by: Kumari S. Prajapati, et al.
Published: (2020-12-01)

Impact of tumor cytoreduction in metastatic prostate cancer
by: Sow Y, et al.
Published: (2019-05-01)

Remission of Membranous Nephropathy after Treatment of Localised Prostate Cancer
by: Daniel Adlington, et al.
Published: (2019-06-01)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
by: Namrata Khurana, et al.
Published: (2020-01-01)

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
by: Tomoyuki Makino, et al.
Published: (2021-04-01)

A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer
by: ZHU Hui, et al.
Published: (2019-10-01)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
by: Aditya Bagrodia, et al.
Published: (2009-01-01)

Characterization of Novel Progression Factors in Castration-Resistant Prostate Cancer Based on Global Comparative Proteome Analysis
by: Ann-Yae Na, et al.
Published: (2021-07-01)

Incidence of prostate cancer in transgender women undergoing androgen deprivation therapy: A review
by: Saurabh Tyagi, et al.
Published: (2023-01-01)

The effect of estradiol add-back: a longitudinal MRI study in prostate cancer patients
by: Orwa Dandash, et al.
Published: (2024-02-01)

Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2021-03-01)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
by: Maryam Labaf, et al.
Published: (2022-11-01)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
by: Hiroji Uemura, et al.
Published: (2022-01-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study
by: Liu JM, et al.
Published: (2018-09-01)

Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations
by: Abraham Morgentaler, et al.
Published: (2015-04-01)